PhotonPharma Launches Phase 1 Clinical Trial for Innovative Cancer Treatment PhotonPharma Inc. is set to begin a Phase 1 clinical trial for Innocell™, an autologous cellular immunotherapy targeting recurrent epithelial ovarian cancer, marking a significant advancement in personalized cancer treatment.

PhotonPharma Launches Phase 1 Clinical Trial for Innovative Cancer Treatment #United_States #Fort_Collins #OvarianCancer #PhotonPharma #Innocell

PhotonPharma Welcomes William Warren, Ph.D., to Board of Directors for Vaccine Innovations PhotonPharma Inc. enhances its board with the appointment of William Warren, Ph.D., a leader in vaccine innovation, emphasizing its cancer therapy advancements.

PhotonPharma Welcomes William Warren, Ph.D., to Board of Directors for Vaccine Innovations #USA #Fort_Collins #PhotonPharma #Innocell #William_Warren

PhotonPharma's CEO Unveils Innovative Autologous Treatment at Major Cancer Conference CEO Dr. Raymond Goodrich will present PhotonPharma's pioneering Innocell™ platform for personalized cancer immunotherapy at the upcoming summit.

PhotonPharma's CEO Unveils Innovative Autologous Treatment at Major Cancer Conference #United_States #Boston #Immunotherapy #PhotonPharma #Innocell

PhotonPharma's New Patent Marks a Breakthrough in Cancer Immunotherapy Development PhotonPharma has received a U.S. patent for its innovative cancer immunotherapy, Innocell™, which promises significant advancements in treating tumors. Discover the technology's potential now.

PhotonPharma's New Patent Marks a Breakthrough in Cancer Immunotherapy Development #United_States #Fort_Collins #Cancer_Immunotherapy #PhotonPharma #Innocell

三井化学、新たな細胞培養ウェルプレートInnoCell(R)を発表 三井化学が高酸素透過性細胞培養ウェルプレートInnoCell(R)を2025年7月に上市。医薬品開発の現場での活用が期待されています。

三井化学、新たな細胞培養ウェルプレートInnoCell(R)を発表 #東京都 #中央区 #三井化学 #医薬品開発 #InnoCell

三井化学が高酸素透過性細胞培養ウェルプレートInnoCell(R)を2025年7月に上市。医薬品開発の現場での活用が期待されています。